Ketolides, which represent the newest generation of macrolide antibiotics, are generally perceived as 'non-inducers' of inducible erm genes. In this paper we investigated the effect of several macrolide and ketolide compounds on expression of the inducible erm(C) gene expressed in E. coli cells. Exposure to 14-member ring macrolide drugs and to azithromycin led to rapid and pronounced increase in the extent of dimethylation of the Erm(C) target residue A2058 in 23S rRNA. When cells were incubated with subinhibitory concentrations of ketolides, the extent of A2058 dimethylation was also increased albeit to a lower level and with slower kinetics than those observed with macrolides. The induction of erm(C) expression by ketolides was further confirmed using a reporter construct which allows for colorimetric detection of induction using a disc-diffusion assay. Most of the tested ketolides, including clinicallyrelevant telithromycin and cethromycin, were able to induce the reporter expression, even though the induction occurred within a more narrow range of concentrations compared to the inducing macrolide antibiotics. No induction of the reporter expression was observed with 16-member ring macrolide antibiotics or with a control drug, chloramphenicol.
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INTRODUCTION
Macrolide antibiotics have a proven record of excellence in the clinical setting.
These are safe and efficient drugs which have been utilized in medical practice for many decades. Widespread use of macrolides has created favorable conditions for the selection of resistant strains. Nowadays, macrolide resistance is prevalent among clinical isolates (10, 15, 18) . The two main mechanisms of macrolide resistance are drug-efflux membrane pumps and modification of the drug target site in the ribosome. The latter is brought about by the action of Erm-type methyltransferases. These enzymes, which likely originated in macrolide producers, methylate a single adenine in 23S rRNA (16) . The target nucleotide residue (A2058 in E. coli) is located in the macrolide binding site and its mono-or di-methylation disturbs the shape and chemical makeup of the drug binding site thereby reducing the affinity of the macrolide to the ribosome (26), (34) (7) .
Dimethylation of A2058 also renders the ribosome resistant to lincosamides and streptogramin B antibiotics which bind to an overlapping site in the ribosome.
A2058 is located in the nascent peptide exit tunnel and modification of its chemical structure by Erm methyltransferases apparently is not favorable for the cell unless macrolide antibiotics are present. Because of that, macrolide producers and later, pathogenic strains targeted by macrolides, have acquired an elegant and efficient strategy that enables them to turn on rRNA modification by Erm only when absolutely necessary.
Cells carrying inducible erm genes, express the methylase only upon exposure of the cell to antibiotics. This is achieved due to the specific secondary structure of the mRNA (reviewed in (37)). In the case of inducible erm(C), the gene encoding the methylase, erm(C), is preceded by a short leader cistron (erm(C)L in Figure 1 ). In the absence of A C C E P T E D 4. macrolides, the ribosome binding site of erm(C) (RBS E ) is sequestered in mRNA secondary structure. Therefore, it is inaccessible to initiating ribosomes and Erm is not expressed. At the same time, the leader ORF erm(C)L is efficiently translated by the ribosomes. When cells are exposed to low concentrations of inducing macrolide antibiotics, the drug-bound ribosome engaged in translation of erm(C)L stalls. The stalled ribosome destabilizes the ground-level mRNA secondary structure and shifts equilibrium to the 'induced' conformation. RBS E becomes accessible and erm(C) can now be translated by the ribosomes which are not yet bound by antibiotics. This type of ribosome stalling, and hence induction of erm(C) expression, depends on the amino acid sequence of the nascent peptide and chemical structure of the antibiotic (21, 22) .
Although the molecular mechanisms leading to ribosome stalling in this system are essentially unknown, they likely involve specific interactions between the ribosome, the nascent peptide and the drug.
The widespread occurrence of inducible erm genes as well as other mechanisms of resistance provided a strong incentive for the development of newer macrolide drugs that can evade resistance. The latest generation of macrolides, the ketolides, appeared to achieve this goal. Three general features distinguish clinically-active ketolides from 14-member ring macrolides of the previous generations: i) the lack of cladinose at C3 position of the lactone ring (in ketolides it is replaced with a keto function), ii) the presence of an 11,12-linked carbamate and iii) the presence of an extended alkyl-aryl side chain ( Figure 2 ). Some of these features are required for the tight binding of ketolides to
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Notwithstanding the general lack of understanding of the mechanisms leading to the drug-dependent ribosome stalling and erm induction, the perceived inability of ketolides to induce erm remains unexplained in molecular terms. In addition, some of the published data suggest that certain ketolides may exhibit from weak to significant induction of erm(B) genes (6, 24, 41) .
The aim of this work was to get better insights into the effect of ketolides on ribosome stalling and possibly the induction of erm(C) expression. We analyzed how exposure of E. coli cells carrying inducible erm(C) to ketolides affects the extent and kinetics of dimethylation of A2058 in rRNA of the large ribosomal subunit. We have also constructed a reporter system capable of sensing ribosome stalling during translation of the leader ORF and used this reporter to demonstrate that ketolides do induce initiation of translation at the start codon of the erm(C) cistron. We conclude that ketolides are generally capable of induction of erm(C) expression. We also show that mutations in the leader peptide sequence differentially affect induction of erm expression by ketolides and cladinose-containing macrolides.
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MATERIALS AND METHODS
Antibiotics, enzymes, chemicals and kits
Antibiotics were from Aventis Pharma (telithromycin, roxithromycin, cethromycin, HMR3004, RU69874, RU3562, RU66252,RU56006, RU70645), Sigma (erythromycin, tylosin, josamycin) and US Pharmacopea (azithromycin, clarithromycin).
Enzymes used for DNA cloning were from Fermentas. γ-[
32 P] ATP was from MP Biomedicals. Luria Bertani (LB) broth components and agar were from Difco.
Isopropyl-beta-D-thiogalactopyranoside (IPTG), and 5-bromo-4-chloro-3-indolyl-β-Dgalactopyranoside (X-Gal) were from Fisher Scientific. All oligonucleotide primers were from Integrated DNA Technologies. All other chemicals were from Fisher Scientific or Sigma Aldrich unless indicated otherwise. Site directed mutagenesis was carried out using the QuikChange XL mutagenesis kit (Stratagene). Total RNA was isolated from E.
coli cells using the RNeasy kit (Qiagen)
Plasmids and bacterial strains
Plasmids directly used in this study are listed in 
Construction of the pERMZα α α α reporter
The erm(C) cassette, including the leader ORF and the erm(C) cistron was PCR amplified from a S. aureus clinical isolate kindly provided by Dr. Shortridge, Abbott
Laboratories. AflII and EcoR1 restriction sites were introduced at the ends of the amplified fragment on the PCR primers. The erm cassette was cloned between the AflII and EcoR1 sites of the pPOT1AE vector to produce pERMCT plasmid ( Figure 3A ).
The AflII site of the pERMCT plasmid was eliminated by cutting the plasmid with AflII restriction enzyme, filling up the DNA ends using Klenow fragment of DNA polymerase I in the presence of four dNTPs and re-ligating the blunt-end linear plasmid.
A new AflII restriction site was then introduced at the codons 3-4 of erm(C) cistron and an Nde1 site was introduced at the initiator AUG codon of the leader ORF by PCR-based mutagenesis. The resulting plasmid was named pERMCM.
The erm(C) portion in pERMCM was then replaced with the segment of the E.
coli lacZ gene encoding the β-galactosidase α-peptide (17) (codons 6-60 of lacZ) using the unique restriction sites AflII and EcoR1 of pERMCM. The final 3738-bp reporter construct was named pERMZα ( Figure 3B ).
MIC Determination
MIC determinations were carried out following the NCCLS recommended protocol (29).
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Kinetics of Erm(C) induction in liquid culture.
A 3 ml overnight culture of ZK796 cells transformed with the erm(C)-containing pERMCT plasmid was diluted 1:100 in fresh LB broth containing 100 µg/ml ampicillin and 0.5 mM IPTG. Culture was incubated at 37°C for 1.5 to 2 hours and split into two flasks. Erythromycin or telithromycin was added to the final concentrations of 0.8 µg/ml or 0.4 µg/ml, respectively. One ml aliquots were removed at the desired time points, RNA was isolated and used as a template for the primer extension analysis of A2058 dimethylation.
Primer extension
The deoxyoligonucleotide primer GTAAAGGTTCACGGGGTC was used to assess the degree of dimethylation of A2058 in E. coli 23S rRNA. 10 pmol of the primer was [ and incubated for 2 hrs. Cells (0.3 A 600 , 1.5 x 10 8 cfu) were added to 5 ml of 0.6% LB agar at 50°C. After brief mixing, the cell suspension was poured on top of 1.5% LB agar plate containing 100 µg/µl ampicillin, 0.5 mM IPTG, and 80 µg/ml X-gal. Once soft agar had solidified, 5 mm diameter Whatmann 3MM paper discs were placed on parafilm and wetted with 5-10 µl of solution of the appropriate antibiotic. Antibiotic-containing discs
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were placed on top of the plates, plates were inverted and incubated for 18-24 hrs at 37°C.
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RESULTS
Activation of Erm(C)-dependent ribosome methylation by ketolides
This work represents part of an extended study of drug-dependent ribosome stalling which utilizes some of the unique advantages of the E. coli system. Therefore, the studies reported in this paper were carried out in E. coli as opposed to a Gram positive organism. Given the high conservation of the ribosome elements involved in interaction with the drug and the nascent peptide, the results obtained in E. coli system are believed to be applicable to other bacteia as well. To study the effect of ketolide antibiotics on the expression of erm(C), an inducible erm(C) cassette from a clinical S. aureus isolate was cloned into an E. coli plasmid pPOT1AE (31) under the control of IPTG-inducible P tac promoter. The resulting plasmid, pERMCT ( Figure 3A ), was transformed into the E. coli tolC -strain ZK796 (40). Introduction of the inducible erm(C) increased erythromycin resistance 8-fold, whereas no obvious changes in resistance to ketolides (telithromycin or cethromycin) or to a peptidyl transferase inhibitor chloramphenicol were observed (Table   1 ). This result was in agreement with previous assertion that Gram-positive bacteria carrying inducible erm remain sensitive to ketolides (1, 2, 19) .
The resistance conferred by erm induction is the result of a complex sequence of events. The development of the resistance phenotype may depend on kinetics of erm induction, on-and off-rates of antibiotic binding, the affinity of the drug for the methylated ribosome, and other parameters. We reasoned that MIC data may not accurately reveal the immediate effect of ketolides on induction of erm expression.
Therefore, we investigated more directly whether exposure of cells that carry inducible erm to ketolide antibiotics leads to dimethylation of A2058 in 23S rRNA. ZK796 cells
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12. is 22 nt-long product, but it is only 20 nt long when 23S rRNA dimethylated at A2058 is used as a template. As can be seen in Figure 4B , incubation of erm-carrying cells with macrolides erythromycin, azithromycin and RU69874 results in dimethylation of A2058 in a significant fraction of cellular 23S rRNA. Importantly, exposure of cells to ketolide drugs, telithromycin or cethromycin, also led to dimethylation of A2058 albeit to a lesser extent than exposure to macrolides.
We then investigated the kinetics of erm(C) induction by a macrolide erythromycin and a ketolide telithromycin. After addition at sub-inhibitory concentrations (ca. 25% of the MIC) of the corresponding drug to the exponential cultures, RNA samples were prepared after defined periods of time and the extent of A2058 dimethylation was assessed by primer extension. Figure 4C shows that upon exposure of cells to erythromycin a significant fraction (10 %) of 23S rRNA becomes dimethylated at A2058 after only 30 min of incubation; the fraction of dimethylated rRNA continues to grow rapidly for the next several hours. In contrast, A2058 in cells exposed to a ketolide
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telithromycin remains essentially unmethylated for at least 2 hrs after which time a slow increase in A2058 dimethylation is observed. Even upon prolonged incubation, the level of rRNA methylation in cells incubated with telithromycin remained lower than that in cells exposed to erythromycin. The slow onset of methylation and a lower overall level of A2058 dimethylation upon the exposure of cells to ketolides could be among the reasons why ketolide MICs are not dramatically affected by the presence of inducible erm genes.
Use of pERMZα α α α reporter to assess erm(C) induction by macrolides and ketolides.
Although the extent of Erm-dependent methylation of 23S rRNA is a more direct readout of erm induction than MIC readings, it is still fairly remote from the act of Notably, telithromycin reproducibly exhibited a stronger inducing activity than cethromycin (compare discs 9 and 10 in Figure 6A ). Neither of the three 16-member-ring macrolides tested (tylosin, spiramycin and josamycin) induced the reporter expression;
this observation agreed with the previously reported results ( Figure 5C ) (38).
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Unexpectedly, exposure to azithromycin, which is known to be a good inducer of erm, did not generate blue coloration ( Figure 6A , disc 4). The experiment was repeated several times with different batches of azithromycin, but with the same result. Further experiments with JM109 cells transformed with the pUC18 vector constitutively expressing LacZ α-peptide led us to believe that this effect is related to specific inhibition by azithromycin of either β-galactosidase activity or of the chromophore generation rather than inability of the drug to induce expression of the reporter (data not shown).
Investigation of this unexpected effect of azithromycin was beyond the scope of the present work.
Altogether, the use of the pERMZα reporter confirmed the notion that ketolides are able to activate expression of the inducible erm(C) gene and thus should be generally viewed as potential inducers.
Alteration of the leader ORF differentially affects induction by macrolides and ketolides
The C-terminal sequence of the erm(C) leader nascent peptide that resides within the ribosome in the drug-induced stalled complex (…-I-F-V-I) bares some similarity to short resistance peptides whose expression renders cells resistant to erythromycin (M-X-I/L-F-V) ('E-peptides') (11, 30, 31, 33, 36). However, the size of the erythromycin resistance peptides is only four-to-six amino acids long while the size of the nascent peptide in the stalled erm leader complex is 9 amino acids in length. We wanted to test whether making erm leader peptide more similar to E-peptides would affect induction.
Two constructs were engineered. In one, pERMZ∆2-4, codons 2 -4 of the erm leader were deleted so that, if the stalling site is not changed, the nascent peptide in the stalled complex is expected to be six amino acids long (MSIFVI). In the second construct, pERMZ7, the same deletion was combined with two additional mutations, Ser 5 
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DISCUSSION
The purpose of this work was to investigate the effect of ketolides, generally One needs to keep in mind that our experiments were carried out in Gram-negtaive E.
coli whereas erm(C) gene apparently originates in Gram-positive bacteria. Expression of inducible erm(C) in E. coli was reported to be 'sluggish' compared to that in S. aureus and the extent of rRNA dimethylation in E. coli is lower than in S. aureus (13, 32) .
However, the fact that ketolides induce erm(C) expression even in E. coli may mean that
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20. In the course of this work, we have constructed a reporter plasmid, pERMZα, which, when present in cells capable of α-complementation, provides a fast and facile way to assay the inducing ability of multiple antibiotics. Several reporters of inducible
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erm expression have been developed in the past utilizing either the full-size β-galactosidase (LacZ) gene or green fluorescent protein (GFP) gene (6, 14, 23, 24) . We believe our reporter, based on the β-galactosidase α-peptide, provides a considerable advantage compared to these previously described systems. The high background of β-galactosidase activity observed with the constructs carrying the entire lacZ gene prevents visual detection of induction on indicator plates. Indeed, when lacZα gene in the pERMZα construct was replaced with complete lacZ, transformed cells formed dark blue colonies even in the absence of the inducing antibiotic -apparently due to the fact that the translation attenuation system is not strong enough to completely prevent translation of the downstream cistron in the erm(C) cassette. The use of GFP generally helps to avoid this problem (6), but slow folding and high stability of GFP may potentially complicate interpretation of the data. We believe our reporter, which provides an easy readout of inducible erm(C) expression without necessity for any specialized equipment, may find broad use in studies of the erm-inducing ability of various antibiotics. The only problem we encountered with our reporter is the unexpected inhibitory effect of azithromycin on β-galactosidase activity. Amongst many tested compounds, azithromycin was the only one which exhibited such inhibition. Nevertheless, the potential ability of other drugs to inhibit directly the activity of β-galactosidase must be kept in mind.
Finally, we also noticed that cells carrying the pERMZ7 construct exhibited a bluish hue on indicator plates -even in the absence of an inducing antibiotic ( Figure 6 ).
This could result from the altered ground-state folding of the mutant mRNA. Another possible explanation is that certain short nascent peptides may stall the ribosome even in 
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